Logo image of ZYBT

ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ZYBT - KYG989MS1016 - Common Stock

2.13 USD
-0.01 (-0.47%)
Last: 12/8/2025, 1:00:39 PM
Fundamental Rating

5

ZYBT gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. ZYBT has an average financial health and profitability rating. ZYBT is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year ZYBT was profitable.
In the past year ZYBT had a positive cash flow from operations.
ZYBT Yearly Net Income VS EBIT VS OCF VS FCFZYBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 20M 40M 60M

1.2 Ratios

Looking at the Return On Assets, with a value of 7.96%, ZYBT belongs to the top of the industry, outperforming 89.01% of the companies in the same industry.
With an excellent Return On Equity value of 13.83%, ZYBT belongs to the best of the industry, outperforming 87.96% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 12.67%, ZYBT belongs to the top of the industry, outperforming 91.62% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for ZYBT is below the industry average of 12.85%.
The 3 year average ROIC (10.57%) for ZYBT is below the current ROIC(12.67%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.96%
ROE 13.83%
ROIC 12.67%
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)10.57%
ROIC(5y)N/A
ZYBT Yearly ROA, ROE, ROICZYBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 5 10 15

1.3 Margins

The Profit Margin of ZYBT (12.95%) is better than 85.86% of its industry peers.
ZYBT's Profit Margin has declined in the last couple of years.
The Operating Margin of ZYBT (16.66%) is better than 86.39% of its industry peers.
In the last couple of years the Operating Margin of ZYBT has declined.
The Gross Margin of ZYBT (54.00%) is better than 65.97% of its industry peers.
ZYBT's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 16.66%
PM (TTM) 12.95%
GM 54%
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
ZYBT Yearly Profit, Operating, Gross MarginsZYBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 10 20 30 40 50

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ZYBT is still creating some value.
Compared to 1 year ago, ZYBT has about the same amount of shares outstanding.
Compared to 1 year ago, ZYBT has an improved debt to assets ratio.
ZYBT Yearly Shares OutstandingZYBT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
ZYBT Yearly Total Debt VS Total AssetsZYBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

ZYBT has an Altman-Z score of 3.34. This indicates that ZYBT is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.34, ZYBT is in the better half of the industry, outperforming 69.11% of the companies in the same industry.
The Debt to FCF ratio of ZYBT is 6.51, which is on the high side as it means it would take ZYBT, 6.51 years of fcf income to pay off all of its debts.
ZYBT has a Debt to FCF ratio of 6.51. This is amongst the best in the industry. ZYBT outperforms 80.63% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that ZYBT is not too dependend on debt financing.
ZYBT has a Debt to Equity ratio (0.02) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 6.51
Altman-Z 3.34
ROIC/WACC1.54
WACC8.24%
ZYBT Yearly LT Debt VS Equity VS FCFZYBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

ZYBT has a Current Ratio of 1.31. This is a normal value and indicates that ZYBT is financially healthy and should not expect problems in meeting its short term obligations.
ZYBT's Current ratio of 1.31 is on the low side compared to the rest of the industry. ZYBT is outperformed by 74.87% of its industry peers.
A Quick Ratio of 0.88 indicates that ZYBT may have some problems paying its short term obligations.
ZYBT's Quick ratio of 0.88 is on the low side compared to the rest of the industry. ZYBT is outperformed by 80.63% of its industry peers.
Industry RankSector Rank
Current Ratio 1.31
Quick Ratio 0.88
ZYBT Yearly Current Assets VS Current LiabilitesZYBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

ZYBT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.94%, which is quite impressive.
The Earnings Per Share has been growing by 528.02% on average over the past years. This is a very strong growth
The Revenue has grown by 43.18% in the past year. This is a very strong growth!
The Revenue has been growing by 854.79% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)21.94%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-64.04%
Revenue 1Y (TTM)43.18%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-11.95%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZYBT Yearly Revenue VS EstimatesZYBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ZYBT is valuated rather expensively with a Price/Earnings ratio of 17.75.
Compared to the rest of the industry, the Price/Earnings ratio of ZYBT indicates a rather cheap valuation: ZYBT is cheaper than 84.29% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.49. ZYBT is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 17.75
Fwd PE N/A
ZYBT Price Earnings VS Forward Price EarningsZYBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

85.86% of the companies in the same industry are more expensive than ZYBT, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ZYBT indicates a somewhat cheap valuation: ZYBT is cheaper than 77.49% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 53.77
EV/EBITDA 10.49
ZYBT Per share dataZYBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

The decent profitability rating of ZYBT may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ZYBT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZHENGYE BIOTECHNOLOGY HOLDIN

NASDAQ:ZYBT (12/8/2025, 1:00:39 PM)

2.13

-0.01 (-0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.33%
Inst Owner ChangeN/A
Ins Owners6.53%
Ins Owner ChangeN/A
Market Cap100.94M
Revenue(TTM)303.21M
Net Income(TTM)39.27M
AnalystsN/A
Price TargetN/A
Short Float %1.97%
Short Ratio0.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.05
Dividend Growth(5Y)N/A
DP40.8%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 17.75
Fwd PE N/A
P/S 2.35
P/FCF 53.77
P/OCF 17.39
P/B 2.51
P/tB 2.73
EV/EBITDA 10.49
EPS(TTM)0.12
EY5.63%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.04
FCFY1.86%
OCF(TTM)0.12
OCFY5.75%
SpS0.9
BVpS0.85
TBVpS0.78
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.51
Profitability
Industry RankSector Rank
ROA 7.96%
ROE 13.83%
ROCE 14.13%
ROIC 12.67%
ROICexc 13.42%
ROICexgc 14.4%
OM 16.66%
PM (TTM) 12.95%
GM 54%
FCFM 4.38%
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)10.57%
ROIC(5y)N/A
ROICexc(3y)10.67%
ROICexc(5y)N/A
ROICexgc(3y)11.51%
ROICexgc(5y)N/A
ROCE(3y)11.8%
ROCE(5y)N/A
ROICexgc growth 3Y-33.64%
ROICexgc growth 5YN/A
ROICexc growth 3Y-34.32%
ROICexc growth 5YN/A
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 6.51
Debt/EBITDA 0.06
Cap/Depr 114.94%
Cap/Sales 9.16%
Interest Coverage 12.67
Cash Conversion 54.97%
Profit Quality 33.8%
Current Ratio 1.31
Quick Ratio 0.88
Altman-Z 3.34
F-Score7
WACC8.24%
ROIC/WACC1.54
Cap/Depr(3y)102.94%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.29%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.94%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-64.04%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)43.18%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-11.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.17%
EBIT growth 3Y573.13%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.72%
FCF growth 3Y1249.56%
FCF growth 5YN/A
OCF growth 1Y-14.81%
OCF growth 3Y988.8%
OCF growth 5YN/A

ZHENGYE BIOTECHNOLOGY HOLDIN / ZYBT FAQ

What is the ChartMill fundamental rating of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) stock?

ChartMill assigns a fundamental rating of 5 / 10 to ZYBT.


Can you provide the valuation status for ZHENGYE BIOTECHNOLOGY HOLDIN?

ChartMill assigns a valuation rating of 4 / 10 to ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT). This can be considered as Fairly Valued.


What is the profitability of ZYBT stock?

ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) has a profitability rating of 6 / 10.


Can you provide the financial health for ZYBT stock?

The financial health rating of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) is 5 / 10.